By Jacob Bell | June 15, 2026
Eli Lilly’s strategic bet on the biotech startup Ajax Therapeutics appears to be paying dividends earlier than anticipated. Emerging clinical data, presented this past weekend at a premier European hematology conference, suggests that the pharmaceutical giant has secured a potent new weapon in the fight against myelofibrosis, a rare and debilitating form of bone marrow cancer.
The experimental drug, acquired through Lilly’s recent multibillion-dollar acquisition of Ajax, has demonstrated promising efficacy in a Phase 1 study, showing the potential to disrupt the established market currently dominated by Incyte’s blockbuster therapy, Jakafi (ruxolitinib). As analysts begin to digest the trial results, the pharmaceutical landscape for blood disorders is bracing for a potential shift in the competitive hierarchy.
Main Facts: A New Mechanism for a Difficult Disease
Myelofibrosis is a chronic, progressive blood cancer characterized by the buildup of scar tissue in the bone marrow, which disrupts the body’s ability to produce healthy blood cells. A hallmark of the disease is a severely enlarged spleen (splenomegaly), which causes intense discomfort and secondary complications.
Current standards of care, primarily JAK2 inhibitors like Incyte’s Jakafi, work by binding to the "active" form of the JAK2 enzyme—a protein that, when mutated, triggers runaway blood cell production. While these drugs have been transformative for many, they are not a panacea. A significant portion of the patient population either fails to respond initially or eventually develops resistance, while others struggle with debilitating side effects, including severe anemia, fatigue, and an increased risk of stroke.
Lilly’s candidate, originating from the Ajax pipeline, employs a distinct "Type II" binding approach. By targeting the JAK2 enzyme in its "inactive" state, the drug is designed to provide a more durable response and potentially overcome the resistance mechanisms that often render traditional JAK inhibitors ineffective. This fundamental difference in molecular design is the cornerstone of Lilly’s bullish outlook for the asset.
Chronology of Development: From Ajax to Lilly
The journey of this asset reflects the fast-paced nature of modern oncology drug development.
- Early Development: Ajax Therapeutics focused its research on the precision targeting of the JAK-STAT signaling pathway, specifically engineering molecules that could bypass the limitations of first-generation inhibitors.
- The Acquisition: Recognizing the potential to address a critical unmet need in myelofibrosis, Eli Lilly moved to acquire Ajax in a deal valued in the billions. The acquisition was framed as a long-term investment into the "next generation" of hematological oncology.
- Phase 1 Initiation: Following the acquisition, the drug entered clinical trials with an eye toward proving safety and efficacy in patients who had already failed or become intolerant to existing JAK2 therapies.
- The European Data Reveal (June 2026): Over the weekend, investigators presented the first comprehensive look at the drug’s performance in a 20-patient cohort at a major medical summit, marking the first time the global oncology community had a clear look at the drug’s potential in a real-world clinical setting.
Supporting Data: Spleen Reduction and Symptom Relief
The data presented in Europe has provided a quantitative foundation for the optimism surrounding the drug. In the study, 20 patients with myelofibrosis—many of whom had previously cycled through active-site JAK inhibitors—were monitored over 12 weeks.
Spleen Volume Reduction
Using body imaging as the primary diagnostic tool, researchers found that 13 out of 20 patients (65%) achieved a 35% or greater reduction in spleen volume. This metric, known in the industry as SVR35, is the gold standard for assessing the clinical utility of a myelofibrosis treatment. An additional four participants showed a spleen deflation between 25% and 34%.
Dose-Response Relationship
The study design utilized a dose-escalation protocol, starting at a baseline and increasing by 25-milligram increments up to 125 milligrams. The data revealed a clear dose-dependent response: as the dosage increased, the efficacy improved, with two additional patients achieving the 35% reduction threshold at the higher dose tiers.
Quality of Life Improvements
Perhaps most compelling to clinicians is the patient-reported outcome data. After a single treatment cycle, 17 out of 20 participants reported a 50% or greater reduction in their total symptom score (TSS). This metric accounts for the "invisible" burdens of the disease, such as chronic pain, night sweats, itching, and exhaustion. For patients, this represents a significant restoration of quality of life, which is often the primary goal in treating chronic, progressive cancers.
Implications: The Shadow Over Incyte
The implications of these results for Incyte are immediate and significant. Incyte has long enjoyed a dominant position in the myelofibrosis market, with Jakafi acting as the company’s primary revenue engine. Last year alone, Jakafi generated approximately $3.1 billion in sales, accounting for 71% of Incyte’s total net product revenue.
Market reaction was swift. Following the presentation of the data, shares of Incyte fell by more than 5% to just under $103 per share on Monday morning. Investors are clearly weighing the risk that Lilly’s drug could capture significant market share if it progresses through larger, pivotal trials successfully.
"Lilly’s drug looks to have the makings of a better Jakafi," wrote Jefferies analyst Faisal Kurshid in a note to clients. This sentiment was echoed by Leerink Partners analyst Andrew Berens, who noted that while the trial is early, the results are "encouraging and suggest meaningful improvements over other investigational agents."
The primary threat to Incyte is the patient population that is currently underserved. If Lilly can demonstrate that its drug remains effective even after a patient has stopped responding to ruxolitinib, it would effectively move the drug to the front of the line for new patients and provide a vital "rescue" therapy for those currently failing on the current standard of care.
Official Responses and Future Outlook
While Eli Lilly has maintained a disciplined stance regarding the trial, the internal sentiment is reportedly high. The company is expected to move quickly to initiate larger, multi-center trials to validate these early findings.
"We are encouraged by the initial data, which supports our hypothesis that a Type II inhibitor could provide a differentiated clinical profile," an internal spokesperson noted, emphasizing that the focus remains on rigorous safety and efficacy testing.
For the medical community, the focus now shifts to the long-term safety profile. While the initial results on efficacy are strong, regulators will be looking for sustained performance and an absence of long-term toxicity—the same hurdles that have complicated other drug candidates in the JAK-inhibitor class.
As the industry moves into the second half of 2026, all eyes will be on Lilly’s clinical trial protocols. Should the drug continue to mirror the success of this initial Phase 1 study, the myelofibrosis market—a space that has seen limited innovation for years—could be on the verge of a significant transformation. For patients, the hope is for a therapy that doesn’t just manage the disease, but does so with greater precision, fewer side effects, and more durable results.
In the high-stakes world of pharmaceutical development, Eli Lilly has effectively fired a warning shot across the bow of its competitors. Whether this translates into a total market reordering remains to be seen, but the data suggests that the "Jakafi era" may finally be facing a credible, and potentially superior, successor.
About the Author
